BMRA · Biomerica Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $5.31M | $5.42M | $5.34M | $18.87M | $7.20M | $6.69M |
| Cost of Revenue | $4.81M | $4.80M | $4.89M | $15.89M | $6.70M | $4.91M |
| Gross Profit | $498.0K | $611.0K | $446.0K | $2.98M | $497.0K | $1.78M |
| R&D | $1.02M | $1.49M | $1.58M | $1.81M | $2.41M | $1.91M |
| SG&A | $4.61M | $5.49M | $6.08M | $5.70M | $4.61M | $2.27M |
| Total Operating Expenses | $5.63M | $6.98M | $7.67M | $7.51M | $7.02M | $4.18M |
| D&A | $87.0K | $81.0K | $84.0K | $100.0K | $104.7K | $105.3K |
| Operating Income | ($5.14M) | ($6.37M) | ($7.22M) | ($4.53M) | ($6.52M) | ($2.40M) |
| Interest Expense | - | - | - | - | $367 | $9 |
| Income Tax | $1.0K | $42.0K | $51.0K | $23.7K | $13.1K | $7.4K |
| Net Income | ($4.97M) | ($5.98M) | ($7.14M) | ($4.53M) | ($6.47M) | ($2.34M) |
| EPS - Basic | ($2.16) | ($2.88) | ($4.00) | ($2.88) | ($4.32) | ($1.84) |
| EPS - Diluted | ($2.16) | ($2.88) | ($4.00) | ($2.88) | ($4.32) | ($1.84) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.40M | $4.17M | $9.72M | $5.92M | $4.20M | $8.64M |
| Accounts Receivable | $731.0K | $947.0K | $722.0K | $773.8K | $1.46M | $1.77M |
| Inventory | $1.49M | $2.38M | $2.06M | $2.42M | $3.21M | $2.85M |
| Accounts Payable | $295.0K | $288.0K | $344.0K | $736.0K | $833.4K | - |
| Current Assets | $4.88M | $7.73M | $12.80M | $9.43M | $9.23M | $14.77M |
| Total Assets | $5.95M | $9.25M | $14.45M | $11.37M | $11.82M | $17.26M |
| Current Liabilities | $1.74M | $2.20M | $1.95M | $2.01M | $1.30M | $1.48M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $1.84M | $2.66M | $2.73M | $3.05M | $2.59M | $3.05M |
| Stockholders' Equity | $4.11M | $6.59M | $11.72M | $8.32M | $9.23M | $14.21M |
| Retained Earnings | ($53.17M) | ($48.20M) | ($42.22M) | ($35.08M) | ($28.39M) | ($21.93M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.84M) | ($5.36M) | ($5.47M) | ($480.5K) | ($5.25M) | ($4.30M) |
| Investing Cash Flow | ($37.0K) | ($115.0K) | ($78.0K) | ($170.3K) | ($295.6K) | ($118.9K) |
| Financing Cash Flow | $2.11M | ($81.0K) | $9.39M | $2.39M | $1.11M | $12.37M |
| CapEx | - | $51.0K | $64.0K | $56.9K | $135.9K | $33.6K |
| Free Cash Flow | - | ($5.41M) | ($5.54M) | ($537.4K) | ($5.39M) | ($4.33M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 9.4% | 11.3% | 8.4% | 15.8% | 6.9% | 26.6% |
| Operating margin | -96.7% | -117.6% | -135.3% | -24.0% | -90.6% | -35.9% |
| EBITDA margin | -95.1% | -116.1% | -133.7% | -23.5% | -89.1% | -34.3% |
| Net margin | -93.6% | -110.4% | -133.7% | -24.0% | -89.9% | -34.9% |
| Free cash flow margin | - | -99.9% | -103.7% | -2.8% | -74.8% | -64.7% |
| FCF / Net income | - | 0.91 | 0.78 | 0.12 | 0.83 | 1.85 |
| R&D / Revenue | 19.3% | 27.5% | 29.7% | 9.6% | 33.5% | 28.5% |
| SG&A / Revenue | 86.8% | 101.3% | 114.0% | 30.2% | 64.0% | 34.0% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -83.7% | -64.6% | -49.4% | -39.8% | -54.7% | -13.6% |
| Return on equity | -121.1% | -90.7% | -60.9% | -54.4% | -70.1% | -16.5% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.80 | 3.51 | 6.58 | 4.69 | 7.10 | 10.00 |
| Quick ratio | 1.95 | 2.43 | 5.52 | 3.49 | 4.63 | 8.07 |
| Cash ratio | 1.38 | 1.89 | 5.00 | 2.94 | 3.23 | 5.85 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | -17772.4x | -266983.1x |
| Equity multiplier | 1.45 | 1.40 | 1.23 | 1.37 | 1.28 | 1.21 |
| Liabilities / Assets | 0.31 | 0.29 | 0.19 | 0.27 | 0.22 | 0.18 |
| Efficiency | ||||||
| Asset turnover | 0.89 | 0.59 | 0.37 | 1.66 | 0.61 | 0.39 |
| Inventory turnover | 3.23 | 2.02 | 2.38 | 6.58 | 2.09 | 1.72 |
| Days sales outstanding | 50d | 64d | 49d | 15d | 74d | 96d |
| Days inventory outstanding | 113d | 181d | 153d | 55d | 175d | 212d |
| Days payable outstanding | 22d | 22d | 26d | 17d | 45d | - |
| Cash conversion cycle | 141d | 222d | 177d | 54d | 203d | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 1.7x | 11.8x | 13.2x | - | - | - |
| P / S | 1.3x | 14.4x | 29.1x | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -1.9% | 1.4% | -71.7% | 162.1% | 7.6% | 28.7% |
| Revenue CAGR (3y) | -34.5% | -9.1% | -7.3% | 53.7% | 7.5% | 4.9% |
| Revenue CAGR (5y) | -4.5% | 0.8% | -1.6% | 26.6% | 7.0% | 6.2% |
| Gross profit growth (YoY) | -18.5% | 37.0% | -85.0% | 499.1% | -72.1% | 37.9% |
| Operating income growth (YoY) | 19.3% | 11.9% | -59.3% | 30.5% | -171.4% | 0.4% |
| Net income growth (YoY) | 16.8% | 16.3% | -57.6% | 30.0% | -176.6% | 2.3% |
| EPS growth (YoY) | 25.0% | 28.0% | -38.9% | 33.3% | -134.8% | -607.7% |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | 2.3% | -930.5% | 90.0% | -24.4% | -84.7% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -37.7% | -43.8% | 40.8% | -9.8% | -35.1% | 257.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-05-31.
Product / service
$5.31M totalClinical Lab$3.18M · 59.9%
Contract Manufacturing$1.07M · 20.1%
Over The Counte$1.05M · 19.8%
Physicians Office$11.0K · 0.2%
Geographic
$5.31M totalAsia$1.72M · 32.3%
North America$1.66M · 31.2%
Europe$1.30M · 24.4%
Middle East$630.0K · 11.9%
South America$8.0K · 0.2%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-8.05
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing BIOMERICA INC against the 5 most active filers in the same SIC group.